bioMerieux (OTCMKTS:BMXMF) Shares Gap Down - Should You Sell?

bioMerieux (OTCMKTS:BMXMF - Get Free Report)'s share price gapped down before the market opened on Monday . The stock had previously closed at $142.45, but opened at $137.51. bioMerieux shares last traded at $137.51, with a volume of 4 shares changing hands.

Wall Street Analyst Weigh In

Separately, Royal Bank Of Canada downgraded bioMerieux from a "moderate buy" rating to a "hold" rating in a research note on Wednesday, May 7th.

bioMerieux Stock Performance

The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.29 and a current ratio of 2.20. The firm's 50-day simple moving average is $137.75 and its two-hundred day simple moving average is $127.39.

bioMerieux Company Profile

bioMérieux SA develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.